FDA Authorizes Marketing of Medasense’s Nociception Monitoring Tech
The FDA granted marketing authorization to Medasense Biometrics’ PMD-200 patient monitor with NOL technology for monitoring nociception.
Tag: De Novo clearance
All
LatestSorry, No Posts Found
All
LatestSorry, No Posts Found
All
Latest
FDA Authorizes Marketing of Medasense’s Nociception Monitoring Tech
The FDA granted marketing authorization to Medasense Biometrics’ PMD-200 patient monitor with NOL technology for monitoring nociception.